AngioDynamics (ANGO) Tops Q4 EPS by 3c; Affirms FY18 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
July 18, 2017 6:00 AM EDTCompany posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance
Q4 net sales of $86.9 million, down 7% year-over-yearQ4 GAAP loss per share of $0.30; adjusted EPS of $0.19Full Year net sales of $349.6 million, down 1% year-over-yearFull Year GAAP earnings per share of $0.19; Adjusted EPS of $0.73, up 22% compared to FY2016Full Year operating cash generation of $55.7 million; free cash flow generation of $52.7 millionALBANY, N.Y., July 18, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive... More
